Open an account

MBX Biosciences

MBX · NASDAQ

$53.50+$1.02 (+1.94%)TodayMarket closed ·
Prev close $52.48

About MBX

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. The company is headquartered in Carmel, Indiana and currently employs 63 full-time employees. The company went IPO on 2024-09-13. The firm is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

Employees
63
Headquarters
Carmel, Indiana
Listed
Sep 13, 2024
Sector
Health Care
Industry
Pharmaceuticals
Website
mbxbio.com

MBX key statistics

Market cap
2.58B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
590.07K
Volume
808.08K
Open price
$52.56
High today
$55.00
Low today
$51.05
52 Week high
$72.64
52 Week low
$13.22

MBX Biosciences (MBX) at a glance

MBX Biosciences (MBX) last traded at $53.50, with a market cap of 2.58B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $51.05 and $55.00. The current price is 4.8% above the day's low and 2.7% below its high.

Volume so far is 808.08K shares, above the average of 590.07K shares a day.

Over the past year MBX Biosciences has ranged from $13.22 to $72.64, and now sits 68% of the way up that range.

MBX Biosciences met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.78 per share against an estimate of -$0.6385.

The average analyst price target is $89.87, 68.0% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

90%of 10 analyst ratings say Buy
  • Buy90.0%
  • Hold0.0%
  • Sell10.0%
Price target · 11 analystsAvg $89.87
Low
$70.70
Now
$53.50
High
$127.05

MBX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 16.0% on average.

  1. Q3 FY24: reported -$2.78 per share against an estimate of -$2.74
  2. Q4 FY24: reported -$0.47 per share against an estimate of -$0.5791
  3. Q1 FY25: reported -$0.71 per share against an estimate of -$0.7777
  4. Q2 FY25: reported -$0.58 per share against an estimate of -$0.7674
  5. Q3 FY25: reported -$0.63 per share against an estimate of -$0.7007
  6. Q4 FY25: reported -$0.49 per share against an estimate of -$0.6155
  7. Q1 FY26: reported -$0.51 per share against an estimate of -$0.5884
  8. Q2 FY26: reported -$0.78 per share against an estimate of -$0.6385

MBX news

  • Press releaseGlobe Newswire

    MBX Biosciences to Participate in Upcoming November Investor Conferences

  • Press releaseGlobe Newswire

    MBX Biosciences to Participate in Upcoming Investor Conferences

  • Vandana Singh

    MBX Biosciences Highlights Sustained Calcium Control In Rare Disease

  • Press releaseGlobe Newswire

    MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

  • Press releaseGlobe Newswire

    MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

  • Press releaseGlobe Newswire

    MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

  • Press releaseGlobe Newswire

    MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

  • Press releaseGlobe Newswire

    MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio

Similar companies

Companies in the same industry as MBX Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.